J Gynecol Oncol.
2022 Jul;33(4):e63. 10.3802/jgo.2022.33.e63.
Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
- Shi T
1 - Xiang L1
- Zhu J2
- Liu J3
- Zhang P2
- Wang H4
- Feng Y3
- Zhu T2
- Zhang Y2
- Yu A2
- Jiang W5
- Wang X6
- Zhu Y7
- Wu S7
- Teng Y8
- Zhang J2
- Jiang R1
- Zhang W9
- Jia H10
- Zang R1
- Affiliations
-
- 1Ovarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
- 2Department of Gynecologic Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China
- 3Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
- 4Department of Gynecologic Oncology, Fudan University Cancer Hospital, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- 5Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
- 6Department of Obstetrics and Gynecology, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 7Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai, China
- 8Department of Obstetrics and Gynecology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- 9Department of Biostatistics, Fudan University, Shanghai, China
- 10Clinical Statistics Center, Shanghai General Hospital, Shanghai, China
- KMID: 2537900
- DOI: http://doi.org/10.3802/jgo.2022.33.e63
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
- A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
- A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
- Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study
- Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study
